Scilex Holding (SCLX) investor relations material

Company overview and business model

• Focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, targeting high unmet needs and large market opportunities.

• Commercial products include ZTlido (lidocaine topical system), ELYXYB (oral solution for migraine), and GLOPERBA (liquid colchicine for gout); pipeline includes SEMDEXA (SP-102), SP-103, and SP-104.

• Employs a patient-first approach and aims to become a leader in non-opioid pain management.

• Has adopted a cryptocurrency treasury strategy, investing in Bitcoin, Ethereum, and other blockchain-linked assets for long-term holdings and yield-generating activities.

Financial performance and metrics

• Audited consolidated financial statements for 2024 and 2025 are incorporated by reference, with a going concern explanatory paragraph from the auditor.

• As of April 30, 2026, 8,491,267 shares of common stock and 29,057,097 shares of Series A Preferred Stock are outstanding.

Use of proceeds and capital allocation

• Will receive up to $144.9 million from the exercise of warrants and conversion of notes, if exercised for cash; proceeds to be used for working capital, R&D, regulatory, clinical trials, acquisitions, investments, business combinations, and debt repayment.

• May allocate a significant portion of proceeds to purchase additional cryptocurrencies as part of its treasury strategy.

• Proceeds from resale of securities by selling securityholders will not go to the company.